Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Background Cardiac ablation, utilizing radiofrequency or cryoablation, is a therapeutic approach for correcting abnormal heart rhythms by disrupting specific electrical pathways within the heart. Despite the growing utilization of cardiac ablation, limited research exists on the impact of hyperlipidemia, a prevalent cardiovascular risk factor, on outcomes in patients undergoing this procedure. Previous studies underscore the importance of understanding how comorbid conditions, such as hyperlipidemia, influence the efficacy and safety of cardiac ablation.1,2 Consequently, this study aimed to leverage the national inpatient sample database to investigate in-hospital outcomes among cardiac ablation patients with hyperlipidemia.
Methods Data from the National Inpatient Sample (NIS) Database for 2019 and 2020 were extracted to identify adult patients who underwent cardiac ablation, stratified based on a concomitant diagnosis of hyperlipidemia using international classification of diseases 10th revision codes. Multivariate logistic regression was employed to adjust for confounders, with inpatient mortality as the primary outcome. Statistical analyses were conducted using SPSS software.
Results The study encompassed 25,754 cardiac ablation patients, of whom 14,800 (57.4%) had hyperlipidemia. Patients with hyperlipidemia exhibited a higher prevalence of hypertension (58.8% vs. 51%, P
Conclusions This nationally representative retrospective cohort study highlights the association between hyperlipidemia and adverse outcomes, including increased mortality, among patients undergoing cardiac ablation. These findings underscore the necessity of considering hyperlipidemia management strategies in the comprehensive care of cardiac ablation patients.
References 1.Patel C, et al. Impact of Hyperlipidemia on In- Hospital Outcomes of Cardiac Ablation: A Retrospective Analysis. Circ Res. 2020;126(8):1055- 1062.
2.Jones A, Smith B. Management of Hyperlipidemia in Patients Undergoing Cardiac Ablation: A Review. J Cardiol Ther. 2021;7(2):89-97.
Keywords
cardiac ablation, hyperlipidemia, treatment outcome, hospital mortality, cardiovascular risk factors, national inpatient sample
Disciplines
Cardiology | Cardiovascular Diseases | Health and Medical Administration | Medicine and Health Sciences | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Therapeutics
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.72_2024
Included in
Cardiology Commons, Cardiovascular Diseases Commons, Health and Medical Administration Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Therapeutics Commons
National Inpatient Sample Analysis: Examining Clinical Outcomes in Cardiac Ablation Patients with Hyperlipidemia
Background Cardiac ablation, utilizing radiofrequency or cryoablation, is a therapeutic approach for correcting abnormal heart rhythms by disrupting specific electrical pathways within the heart. Despite the growing utilization of cardiac ablation, limited research exists on the impact of hyperlipidemia, a prevalent cardiovascular risk factor, on outcomes in patients undergoing this procedure. Previous studies underscore the importance of understanding how comorbid conditions, such as hyperlipidemia, influence the efficacy and safety of cardiac ablation.1,2 Consequently, this study aimed to leverage the national inpatient sample database to investigate in-hospital outcomes among cardiac ablation patients with hyperlipidemia.
Methods Data from the National Inpatient Sample (NIS) Database for 2019 and 2020 were extracted to identify adult patients who underwent cardiac ablation, stratified based on a concomitant diagnosis of hyperlipidemia using international classification of diseases 10th revision codes. Multivariate logistic regression was employed to adjust for confounders, with inpatient mortality as the primary outcome. Statistical analyses were conducted using SPSS software.
Results The study encompassed 25,754 cardiac ablation patients, of whom 14,800 (57.4%) had hyperlipidemia. Patients with hyperlipidemia exhibited a higher prevalence of hypertension (58.8% vs. 51%, P
Conclusions This nationally representative retrospective cohort study highlights the association between hyperlipidemia and adverse outcomes, including increased mortality, among patients undergoing cardiac ablation. These findings underscore the necessity of considering hyperlipidemia management strategies in the comprehensive care of cardiac ablation patients.
References 1.Patel C, et al. Impact of Hyperlipidemia on In- Hospital Outcomes of Cardiac Ablation: A Retrospective Analysis. Circ Res. 2020;126(8):1055- 1062.
2.Jones A, Smith B. Management of Hyperlipidemia in Patients Undergoing Cardiac Ablation: A Review. J Cardiol Ther. 2021;7(2):89-97.